Details of the Drug
General Information of Drug (ID: DMI7FNZ)
Drug Name |
6-Benzylsulfanyl-9H-purine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-benzylsulfanyl-9H-purine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 242.3 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||